AzTrials
AzTrials

Pre-Exposure ProphylaxisNCT05991869

Leveraging Electronic Health Record Data in a Risk Prediction Model to Increase HIV PrEP Intake in Primary Care

A study testing Point-of-care decision support intervention in people with Pre-Exposure Prophylaxis, run by Kaiser Permanente at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Kaiser Permanente Northern California (KPNC) has been a national leader in implementation of HIV preexposure prophylaxis (PrEP), a daily antiretroviral pill that is more than 99% effective in preventing HIV acquisition. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Pre-Exposure Prophylaxis
What is being tested?
Point-of-care decision support intervention
Could I receive a placebo?
No, everyone receives an active treatment
How many people
121 participants
Where
1 siteUnited States
Study dates
1 Jun 2021to 31 Oct 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Primary care provider at Kaiser Permanente San Francisco Medical Center
  • Provide primary care to adult patients
  • more than 150 people without HIV on their primary care physician panel.

Who cannot join

  • -

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Kaiser Permanente Northern California Division of Research

    Oakland, California, 94612

Other trials in United States

About this study

Official title: Randomized Trial Leveraging Electronic Health Record Data in a Risk Prediction Model to Increase HIV PrEP Uptake in Primary Care.

Kaiser Permanente Northern California (KPNC) has been a national leader in implementation of HIV preexposure prophylaxis (PrEP), a daily antiretroviral pill that is more than 99% effective in preventing HIV acquisition. However, many patients at risk for HIV at KPNC are not yet using PrEP, resulting in preventable infections each year. In prior work, the study team developed and validated a prediction model that used electronic health record (EHR) data from 3.7 million KPNC members to identify patients at high risk of HIV acquisition but not using PrEP. The model substantially outperformed models based only on CDC criteria for PrEP use, particularly for Black patients, a population with high HIV incidence and lower PrEP uptake. The objective of this proposal is to evaluate the feasibility of implementing this EHR-based model at the point of care to increase PrEP referrals and uptake at KPNC. The specific aims of this project are to 1) conduct provider focus groups to identify barriers and facilitators to PrEP referrals and to optimize the delivery mechanism of our clinical decision support intervention, 2) evaluate the feasibility and acceptability of a clinical decision support intervention for primary care providers (PCPs) to increase PrEP referrals and uptake among high-risk patients, and 3) assess patient- and provider-based characteristics associated with PrEP referrals and uptake. To accomplish these aims, the study team proposes a randomized controlled trial of a clinical decision support intervention for PrEP, which involves alerting KP San Francisco (KPSF) Adult and Family Medicine PCPs about patients identified by our prediction model as being at high risk for HIV acquisition prior to in-person clinic visits. We will compare PrEP referrals and uptake among patients who are seen by PCPs randomized to intervention and usual care study arms using an intention-to-treat analysis.

Read the detailed description

Study Design This is a randomized controlled trial among PCPs at KPSF to evaluate the feasibility of implementing a decision support intervention for PrEP and its impact on PrEP referrals and uptake among patients predicted to be at high risk for incident HIV infections. Aim 1 will consist of focus groups with PCPs to identify barriers and facilitators to PrEP referrals and to optimize the intervention. After first testing the proposed study intervention with two PCPs in each study arm, Aim 2 will compare PrEP referrals and uptake between members who are seen by PCPs randomized to intervention and usual care study arms. Aim 3 will evaluate provider- and patient-based factors associated with PrEP referrals and uptake among patients in the intervention arm. The trial will randomly allocate PCPs at KP San Francisco to one of two arms: 1) intervention arm that includes clinical decision support for PrEP referrals prior to visits scheduled with patients flagged as high-risk by the prediction model, or 2) usual care, with an estimated 50 PCPs in each arm. Eligible PCPs will be contacted by the study team prior to enrollment and given an opportunity to opt out of participating in this study. PCPs randomized to the usual care arm will not receive the clinical decision support intervention. The intervention will be conducted over 8 months.

Setting. KPNC is a large healthcare delivery system that provides integrated pharmacy, laboratory, and medical care to more than a third of insured individuals in California. KPSF has been chosen as the study site given the disproportionate burden of HIV in this KPNC service area. At KPSF, there are 121 Adult and Family Medicine (AFM) PCPs serving approximately 189,000 patients.

Subjects. The study team will recruit 10-15 PCPs each from the two KPSF clinical sites in San Francisco prior to randomization. Providers will be recruited at routine staff meetings and through email invitations for a one-time, 60- minute, audio-recorded focus group. The study team will assess what information PCPs would like to have included in the clinical decision support tool. Recognizing that time constraints are a barrier to all healthcare interventions, we will seek feedback from PCPs regarding their preferences for intervention delivery and timing, as well as their perceptions of facilitators and barriers to acting on the intervention. Open-ended questions will minimize bias and allow for unanticipated themes to emerge.

Randomization. PCPs who meet study criteria and do not opt-out will be randomized to one of the two study arms in a 1:1 ratio. There are 12 providers who care for both HIV-infected and uninfected patients, and allocation of this subset of providers will be balanced between the trial arms. To ensure this, the study team will use simple randomization to assign the 13 PCPs who care for both HIV-infected and uninfected patients to intervention or usual care and then use simple randomization again to assign the remaining 109 PCPs.

Specificity of the prediction model. The prediction model acts as a screening test to be followed by a provider's clinical evaluation. The study team expects that some patients with scores indicating an elevated risk for HIV acquisition will not have clinical indications for PrEP. The relationship between PCPs and patients is critical given the sensitive nature of sexual health discussions. In addition, prior to initiation of treatment with PrEP, patients will attend visits where a member of the dedicated KPSF PrEP team (NP or MD) will assess HIV risk and discuss PrEP indications, follow-up, side effects, and contraindications.

Scalability of the intervention outside KPNC. Even if the intervention is successful within KPNC, other health settings outside KPNC will need to adopt technology solutions to update risk scores, automate lists of patients with elevated risk scores, identify eligible appointments, and successfully deliver interventions to providers. While the study team's robust model that included 44 EHR variables provided the greatest predictive value for incident HIV, simpler models that included only a handful of key variables also improved identification of patients who may benefit from PrEP. The study results will provide a roadmap for successful implementation at other institutions, even if technology and EHR resources are more limited.

Being tested
Point-of-care decision support intervention
Keywords
HIV, Pre-Exposure Prophylaxis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Point-of-care decision support interventionBehavioural

    PCPs notified by EHR messages if they had an upcoming in-person or video visit with an eligible patient who had a predicted risk of incident HIV diagnosis of 0.2% or higher. Study team members manually sent messages marked as "high priority" one business day prior to scheduled visits, alerting PCPs that a patient may be at increased risk for acquiring HIV and may benefit from a conversation about PrEP. Additional information was provided about the study, the prediction model, clinical indications for PrEP, strategies for initiating discussions about HIV prevention and PrEP, and how to refer patients to KPSF's PrEP program. Messages did not include the numeric predicted HIV risk from the model. PCPs received a maximum of two messages per day; with the two patients with the highest predicted risk were selected. Patient with multiple visits were flagged no more than once monthly.

Study groups in NCT05991869
Study groupRoleWhat they receive
InterventionExperimentalNot described
Receives: Behavioral: Point-of-care decision support intervention
Usual CareNo interventionNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cumulative risk (%) of linkage to PrEP

    linkage to PrEP care within 90 days of the first encounter, defined as first of following: PrEP discussion (ICD-10 Z29.8), referral (measured by PrEP referrals and appointments booked through e-consult, a provider-to-provider community platform embedded in the EHR ), or prescription fill for emtricitabine coformulated with tenofovir disoproxil fumarate or with tenofovir alafenamide

    Measured: Within 90 days after PrEP referral.

Secondary outcomes (3)
  1. Cumulative risk (%) of PrEP Prescription fill only

    PrEP prescription fill within 90 days of the first encounter defined as pharmacy fills for emtricitabine coformulated with tenofovir disoproxil fumarate or with tenofovir alafenamide

    Measured: Within 90 days after first encounter

  2. Cumulative risk (%) of HIV Testing

    Physician orders for HIV testing

    Measured: within 90 days of first encounter

  3. Cumulative risk (%) of STI Testing

    Physician orders for any testing for bacterial STIs, including chlamydia, gonorrhea, or syphilis

    Measured: within 90 days of first encounter

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Aug 2023
  2. Study start1 Jun 2021
  3. Primary completion30 Nov 2021
  4. Study completion31 Oct 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
121 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05991869
Sponsor's protocol ID
DelSciPrEP 2021
Status last verified
Aug 2023
First submitted
4 Aug 2023
Last updated
15 Aug 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: There is no plan to make individual participant data available to other researchers.

Publications

  • Volk JE, Leyden WA, Lea AN, Lee C, Donnelly MC, Krakower DS, Lee K, Liu VX, Marcus JL, Silverberg MJ. Using Electronic Health Records to Improve HIV Preexposure Prophylaxis Care: A Randomized Trial. J Acquir Immune Defic Syndr. 2024 Apr 1;95(4):362-369. doi: 10.1097/QAI.0000000000003376.

    PubMed 38412047

Questions about this trial

What is this clinical trial studying?

A study testing Point-of-care decision support intervention in people with Pre-Exposure Prophylaxis, run by Kaiser Permanente at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cumulative risk (%) of linkage to PrEP (time frame: Within 90 days after PrEP referral.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05991869, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Aug 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in